WinstonWınston
Back
Stock

Onward Medical N.V.

ONWD.BR
25
Biotechnology · Healthcare
Price
€2.74
+0.07 (+2.81%)
Market Cap
€127.9M
Exchange
Euronext Brussels
Winston Score
25
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Sep 12, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
Growth
Good
Cash Flow
Weak
Stability
Good
Valuation
Data not available

Share count rising — dilution

+47.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 30.2M (2021) → 44.6M (2025)

§Winston Score History

The full picture

Onward Medical N.V. is a medical technology company dedicated to developing innovative therapies for spinal cord injuries, operating both within the Netherlands and internationally. Among its primary offerings is ARCEX, a non-invasive, external platform. This system incorporates a wearable stimulator and a wireless programmer, designed to restore or significantly enhance hand and arm motor function for individuals living with spinal cord injuries. Complementing this is ARCIM, an implantable platform. ARCIM features an implantable pulse generator and a lead positioned near the spinal cord, empowering individuals with chronic paralysis to regain the ability to stand and walk, often with minimal or no external assistance. The company is also currently advancing the Up-LIFT Trial, a clinical study evaluating the safety and efficacy of ARCEX Therapy in restoring strength and mobility in the upper extremities of those affected by spinal cord injury. Established in 2014, Onward Medical N.V. maintains its headquarters in Eindhoven, Netherlands.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+254.4% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+23.4% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

€12M/ year

Flat (-1% vs prior year)

325.9% of revenue

18.1x the sector average (18%)

Steady R&D investment year-over-year

Cash Runway

~9 months

€82M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Strong grower

Onward Medical N.V. is growing revenue at 254% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
69.0%
Premium pricing power — 69.0% gross margin
Profit after running costs
Operating Margin
-557.1%
Losing money on operations — -557.1%
Return on the money invested
ROCE
-51.9%
Weak — -51.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+438.4%
Fast-growing sales (+438.4% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-685.5%
Burning cash (-685.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.19
Conservative — low debt load (0.19)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial